Latest News

Seven of the states with the largest reductions in uninsured rates since the implementation of the Affordable Care Act have both expanded Medicaid and established a state-based exchange or a state-federal partnership.
Using surgery to promote weight loss and improve health is associated with improve mortality. This study sought information on whether survival benefits extended to patients at higher ages.
Dr Georges Benjamin Discusses the Importance of Diversity in Healthcare
A lack of diversity among healthcare providers can adverse effects for the communities they serve, explained Georges Benjamin, MD, executive director of the American Public Health Association.
The study, while small, suggests a scalable solution that would allow payers address diabetes prevention and health disparities.
Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.
What we're reading, February 10, 2016: 2 companies change how consumers purchase medicines online; CMS memo reveals the government is mulling changes to Medicare reimbursement; and Johns Hopkins will transplant HIV-positive organs to HIV-positive recipients.
As physicians and researchers question whether certain treatments for early signs of breast cancer are necessary, the first large US study will seek to determine the best way to manage ductal carcinoma in situ.
Innovation has remained high on the administration’s agenda, as is evident from the allocations to tackle climate changes as well as find treatments for devastating health conditions.
CMS has already delayed Medicaid managed care once, pushing the start date back to at least March 1, 2016.
Julia Adler-Milstein, PhD, explains the importance of technology as a supporting factor in healthcare delivery, saying that it will enable patients to access their data and become more involved in their healthcare.
A. Mark Fendrick, MD, co-editor-in-chief of The American Journal of Managed Care and director of the University of Michigan Center for Value-Based Insurance Design, testified before a Michigan senate subcommittee on the benefit of clinical nuance.
Mexico is the perfect example of how Coke and Pepsi are investing heavily in the next generation of soda drinkers, and the country has the highest rates of obesity in the world.
Widespread adoption of telemedicine has not been documented, and a session at the 2016 National Health Policy Conference hosted by AcademyHealth addressed some of the current challenges.
What we're reading, February 9, 2016: Novartis signs 2 performance-based deals for its new heart drug; 8 states significantly reduced uninsured rates; and the Obama administration will ask for $1.8 billion to prepare to fight the Zika virus.

From the Journals

An overview of patient assistance programs at Smilow Cancer Hospital at Yale-New Haven, including their innovative hospital-based explanation of benefits form, which can eliminate patient responsibilities and help expedite the turnaround times for payment processing with copay assistance.
The cost issues with immuno-oncology agents are real, but so is the value that they bring to the table. How can we improve access to these agents at a reasonable cost?
Ensuring rapid, appropriate, and sustainable access to immuno-oncology therapies for patients in Europe: what role can policies play?
To address the nationwide concern of costly immunotherapy agents, this article features health system inpatient and outpatient strategies that can help mitigate their costs.
Advances made in the field of immuno-oncology (I-O) in 2015 have greatly expanded our understanding of I-O and added more complexity to its value assessment.
Supporting, funding, and protecting the research and development of new medicines and new treatments is more critical, now than ever, to provide better treatments and better outcomes to all cancer patients.
Re-analysis of US Preventive Services Task Force colorectal cancer screening guidelines shows that every-3-year screening with multi-target sDNA could address poor performance of recommended annual testing.
The translation of immuno-oncology agents from the research to the practice arena may provide significant clinical benefit to patients with difficult-to-treat malignancies. The further development and marketing of these agents could escalate the discussion on care equity in a time of constrained resources.
Assessment of the timing of histologic and molecular testing indicates that testing occurred prior to treatment initiation for most patients with metastatic non–small cell lung cancer.
x-button
Featured Content
Feature
Diabetes Compendium
Oncology Compendium
COPD Compendium
Reimbursement Compendium

Most Popular

AJMC Strategic Alliance

$vacMongoViewPlus$